Compare Celsius Holdings, Inc. (CELH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Mesoblast Limited — how do they compare? Celsius Holdings, Inc. trades at $28.05 (market cap $6.89B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Celsius Holdings, Inc. is far larger — about 3.2× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | MESO | |
|---|---|---|
Market Cap | $6.89B | $2.16B |
Sector | Consumer Staples | Technology |
52-Week High | $64.86 | $20.96 |
52-Week Low | $23.77 | $12.88 |
Enterprise Value | $8.68B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.77, up 16.83% in 24 hours, but technical indicators signal a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates, with revenue growth slowing to 11% year-over-year. Recent news includes an analyst downgrade and leadership changes amid an organizational realignment. Valuation metrics remain elevated with a P/E of 120.74 and P/S of 2.37.
The outlook is mixed: strong analyst consensus (95.65% buy ratings) and a $44.08 price target suggest upside, but risks include core brand weakness, margin pressure, and a pending legal investigation. Investors should weigh growth potential from Alani Nu and Rockstar integrations against execution challenges and high valuation multiples.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
